Skip to main content
SpringerLink
Log in

Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

The nucleos(t)ide reverse transcriptase inhibitors, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF), and the non-nucleoside reverse transcriptase inhibitor, rilpivirine, are now available as a fixed-dose single-tablet regimen (emtricitabine/rilpivirine/tenofovir DF; Complera®, Eviplera®) for the treatment of adults infected with HIV-1. In treatment-naïve adults, once-daily emtricitabine/rilpivirine/tenofovir DF was noninferior to once-daily emtricitabine/efavirenz/tenofovir DF with regard to establishing virological suppression over 96 weeks of therapy in a randomized, open-label, phase IIIb study (STaR). These data confirmed the findings of a pooled subset analysis of two earlier 96-week, double-blind, phase III trials (ECHO and THRIVE) in which treatment-naïve adults received either rilpivirine or efavirenz in combination with emtricitabine/tenofovir DF. However, the virological benefit of emtricitabine/rilpivirine/tenofovir DF in this setting appeared limited in patients with low CD4+ cell counts or high viral loads at baseline. In 48-week phase IIIb (SPIRIT) and IIb (Study 111) trials in treatment-experienced patients already virologically suppressed with a single- or multiple-tablet antiretroviral regimen and without prior virological failure, switching to once-daily emtricitabine/rilpivirine/tenofovir DF maintained virological suppression and was noninferior to remaining on a more complex multiple-tablet regimen in this regard. Emtricitabine/rilpivirine/tenofovir DF is generally well tolerated and appears to have a more favourable tolerability profile than emtricitabine/efavirenz/tenofovir DF. Thus, emtricitabine/rilpivirine/tenofovir DF is a welcome addition to the other single-tablet regimens currently available for the treatment of HIV-1 infection, providing a convenient and effective option for some adults who are treatment-naïve, as well as those who are already virologically suppressed on their current treatment regimen and wish to switch because of intolerance or to simplify their regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17):1497–503.

    Article  CAS  PubMed  Google Scholar 

  2. Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med. 2012;2(4):a007161.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (updated November 2013. All changed text is cast in yellow highlight.). 2014. http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv_v15_is1_Rev.pdf. Accessed 16 Oct 2014.

  4. European AIDS Clinical Society. Guidelines version 7.02. 2014. http://eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf. Accessed 16 Oct 2014.

  5. US Department of Health and Human Services panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed 16 Oct 2014.

  6. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection 2014 recommendations of the International Antiviral Society-USA Panel. JAMA. 2014;312(4):410–25.

    Article  CAS  PubMed  Google Scholar 

  7. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. JAIDS. 2004;36(3):808–16.

    PubMed  Google Scholar 

  8. Kaya S. HIV treatment with once-daily single tablet regimens. J Virol Antivir Res. 2013;2(1). doi:10.4172/2324-8955.1000105.

  9. Molina JM. Efficacy and safety of once-daily regimens in the treatment of HIV infection. Drugs. 2008;68(5):567–78.

    Article  CAS  PubMed  Google Scholar 

  10. Gilead Sciences Limited. Eviplera 200/25/245 mg film-coated tablets: EU summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002312/WC500118802.pdf. Accessed 16 Oct 2014.

  11. Gilead Sciences Inc. Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarat) tablets, for oral use: US prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202123s016lbl.pdf. Accessed 16 Oct 2014.

  12. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–27.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Kulkarni R, Feng JY, Miller MD, et al. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. Antivir Res. 2014;101:131–5.

    Article  CAS  PubMed  Google Scholar 

  14. Porter DP, Kulkarni R, Fralich T, et al. Week 96 analyses of emergent drug resistance from the STaR study: rilpivirine/emtricitabine/tenofovir DF vs. efavirenze/emtricitabine/tenofovir DF single-tablet regimen [poster no. 83].International Workshop on Antiviral Drug Resistance: 3–7 Jun 2014; Berlin.

  15. Nelson MR, Elion RA, Cohen CJ, et al. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE studies. HIV Clin Trials. 2013;14(3):81–91.

    Article  CAS  PubMed  Google Scholar 

  16. White K, Van Eygen V, Vingerhoets J, et al. Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naive HIV-infected adults with ≤100,000 c/mL baseline viral load [abstract no. P187]. In: 18th Annual Conference of the British HIV Association: 18–20 Apr 2012; Birmingham (UK).

  17. Behrens G, Rijnders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS. 2014;28(4):168–75.

    Article  PubMed  Google Scholar 

  18. Palella FJJ, Fisher M, Tebas P, et al. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants [erratum published in AIDS. 2014, 28(13), pp. 199–2000]. AIDS. 2014;28(3):335–44.

    Article  CAS  PubMed  Google Scholar 

  19. Mills A, Cohen C, Dejesus E, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. HIV Clin Trials. 2013;14(5):216–23.

    Article  CAS  PubMed  Google Scholar 

  20. Porter DP, Kulkarni R, Fralich T, et al. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110). JAIDS. 2014;65(3):318–26.

    CAS  PubMed  Google Scholar 

  21. Rimsky L, Van Eygen V, Hoogstoel A, et al. 96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18(8):967–77.

    Article  CAS  PubMed  Google Scholar 

  22. Cohen C, Wohl D, Arribas J, et al. STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF in ART-naive adults through week 96 [abstract no. LBPE7/17 plus poster]. In: 14th European AIDS Conference: 16–19 Oct 2013; Brussels.

  23. Cohen C, Wohl D, Arribas JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS. 2014;28(7):989–97 (Plus supplementary digital content).

    Article  CAS  PubMed  Google Scholar 

  24. Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. JAIDS. 2012;60(1):33–42.

    CAS  PubMed  Google Scholar 

  25. Mathias A, Menning M, Wiser L, et al. Bioequivalence of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate single tablet regimen. J Bioequiv Bioavail. 2012;4(7):100–5.

    CAS  Google Scholar 

  26. Custodio JM, Yin X, Hepner M, et al. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection. J Clin Pharmacol. 2014;54(4):378–85.

    Article  PubMed  Google Scholar 

  27. Moss D, Siccardi M, Khoo S, et al. The interactions of rilpivirine with drug transporters in vitro [abstract no. 616]. In: 19th Conference on Retroviruses and Opportunistic Infections: 5–8 Mar 2012; Washington.

  28. Cohen C, Wohl D, Arribas J, et al. STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF has non-inferior efficacy compared to efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes [abstract no. TUPE284 plus poster]. In: 7th International AIDS Society Conference on HIV Pathogenesis and Treatment: 30 Jun–3 Jul 2013; Kuala Lumpur.

  29. Wilkins E, Cohen C, Wohl D, et al. STaR Study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults regardless of baseline viral load and CD4+ count. HIV Med. 2013;14:55. In: Plus poster presented at the 19th Annual Conference of the British HIV Association: 16–19 Apr 2013; Manchester.

  30. Cohen C, Wohl D, Arribas J, et al. STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is noninferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults co-infected with HBV or HCV (poster no. P_14). In: 9th International Workshop on HIV & Hepatitis Co-Infection: 30–31 May 2013; Rome.

  31. Henry K, Wohl D, Cohen C, et al. STaR: single tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains noninferiority to efavirenz/emtricitabine/tenofovir DF through week 48 in subjects >50 years old (poster no. P_27). In: 4th International Workshop on HIV & Aging: 30–31 Oct 2013; Baltimore.

  32. Brinson C, Segal-Maurer S, Brar I, et al. Star: virologic outcomes and safety in ART-naive adult females for single-tablet regimen rilpivirine/emtricitabine/tenofovir DF compared to efavirenz/emtricitabine/tenofovir DF at week 48 [abstract no. H-655 plus oral presentation]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 10–13 Sep 2013; Denver (CO).

  33. Cohen C, Wohl D, Arribas J, et al. STaR: rilpivirine/emtricitabine/tenofovir DF is noninferior to efavirenz/emtricitabine/tenofovir DF in naive adults Latino, Black & White subpopulations—week 48 results (poster no. P24). In: HIV Drug Therapy in the Americas Congress: 13–15 Jun 2013; Sao Paulo.

  34. Pallela F, Tebas P, Fisher M, et al. Efficacy of switching to rilpivirine/emtricitabine/tenofovir DF from boosted PI in HIV-1 virologically suppressed patients with or without the K103N (abstract). J Int AIDS Soc. 2013; 16:23. In: Plus poster presented at the HIV Drug Therapy in the Americas Congress: 13–15 Jun 2013; Sao Paulo.

  35. Palella F, Fisher M, Tebas P, et al. SPIRIT: switching to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression through week 48 in patients co-infected with HBV or HCV (poster no. P_21). In: 9th International Workshop on HIV & Hepatitis Co-Infection: 30–31 May 2013; Rome.

  36. Morales-Ramirez J, Fisher M, Palella F, et al. SPIRIT: simplifying to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression through week 48 in the Hispanic/Latino subpopulation (oral presentation no. 34). In: 16th Pan-American Infectious Disease Conference: 28 May–1 Jun 2013; Santiago.

  37. Mounzer K, Palella F, Slim J, et al. SPIRIT: simplifying to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor regimen maintains HIV suppression in the Black subgroup (abstract no. H-656 plus poster). In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 10–13 Sep 2013; Denver (CO).

  38. Shamblaw D, Palella F, Ruane P, et al. Switching to the single-tablet regimen (STR) emtricitabine/rilpivirine/tenofovir DF (FTC/RPV/TDF) from a ritonavir-boosted protease inhibitor (PI+RTV) and two nucleoside reverse transcriptase inhibitors maintains HIV suppression and is well tolerated in HIV-1 subjects at week 24 regardless of age: SPIRIT study (abstract no. H-556 plus oral presentation). In: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy: 9–12 Sep 2012; San Francisco.

  39. Wilkins E, Fisher M, Palella F, et al. SPIRIT: Switching to rilpivirine/emtricitabine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48 regardless of viral load or CD4+ count prior to initiation of ARV therapy (abstract). HIV Med. 2013; 14: 54–55. In: Plus poster presented at the 19th Annual Conference of the British HIV Association: 16–19 Apr 2013; Manchester.

  40. Nelson M, Gazzard B, Walmsley S, et al. Pooled week 48 safety and efficacy results from ECHO and THRIVE phase III trials comparing rilpivirine vs. efavirenz in treatment-naïve HIV-1-infected patients receiving FTC/TDF [poster no. P175]. In: 17th Annual Conference of the British HIV Association: 6–8 Apr 2011; Bournemouth.

  41. Shave A, Palella F, Tebas P, et al. Switching PI to rilpivirine in combination with Truvada as a single-tablet regimen. Week 24 results [oral presentation]. Association of Nurses in AIDS Care Annual Conference: 15–17 Nov 2012; Tucson (AZ).

  42. Cohen C, Molina JM, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the double-blind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults [conference report]. In: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: 17–20 Jul 2011; Rome.

  43. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011;378(9787):238–46.

    Article  CAS  PubMed  Google Scholar 

  44. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011;378(9787):229–37.

    Article  CAS  PubMed  Google Scholar 

  45. Sanford M. Rilpivirine. Drugs. 2012;72:525–41.

    Article  CAS  PubMed  Google Scholar 

  46. Creticos C, McDonald C, Segal-Maurer S, et al. STaR: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF is safe and well-tolerated with efficacy comparable to efavirenz/emtricitabine/tenofovir DF in ART-naive females at week 96 (poster no. 16). In: 4th International Workshop on HIV and Women, from Adolesence through Menopause: 13–14 Jan 2014; Washington (DC).

  47. Bernardini C, Maggiolo F. Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera/Eviplera) in the treatment of HIV infection. Patient Prefer Adher. 2013;7:531–42.

    Google Scholar 

  48. Patel N, Miller CD. New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. HIV AIDS. 2012;4:61–71.

    Google Scholar 

  49. Imaz A, Podzamczer D. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy. AIDS Rev. 2012;14(4):268–78.

    PubMed  Google Scholar 

  50. Flamm J, Shamblaw D, Ruane P, et al. Comparison of pharmacy costs after switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from a ritonavir-boosted protease inhibitor and 2 nucleoside reverse transcriptase inhibitors [abstract]. J Managed Care Pharm. 2012;18(7):544–5.

    Google Scholar 

  51. Gilead Sciences. Study to evaluate switching from a regimen consisting of the efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (STR) to the emtricitabine/rilpivirine/tenofovir disoproxil fumarate STR [ClinicalTrials.gov identifier NCT01286740]. US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov. Accessed 16 Oct 2014.

  52. Cohen C, Bloch M, Wohl D, et al. STaR study: single-tablet regimen rilpivirine/emtricitabine/tenofovir DF maintains non-inferiority to efavirenz/emtricitabine/tenofovir DF in ART-naive adults through week 96 with a favourable safety profile for abnormal dreams and dizziness [poster no. WEPE064]. In: 20th International AIDS Conference: 20–25 Jul 2014; Melbourne.

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered the opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Emma Deeks is a salaried employer of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emma D. Deeks.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deeks, E.D. Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Review of Its Use in HIV Infection. Drugs 74, 2079–2095 (2014). https://doi.org/10.1007/s40265-014-0318-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0318-1

Keywords

Search

Navigation